Clinical Trials Browser

Carcinoma, Hepatocellular × enfortumab vedotin × Gastrointestinal × Clear all

NCT06553885 2026-01-29

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Colorectal Neoplasms